Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Mar 21 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release regarding approvals from the USFDA for Tofacitinib Tablets. The company received final approval for the five milligram strength and tentative approval for the ten milligram strength of the drug. Tofacitinib is used to treat various forms of arthritis and ulcerative colitis, and will be manufactured in Ahmedabad, India. The press release highlights Zydus's eligibility for shared exclusivity for the five milligram strength due to its early application.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated March 21, 2023, titled "Zydus receives final and tentative Approval from the USFDA for Tofacitinib Tablets, 5 mg and 10 mg, respectively".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases